Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3843-3848

  Iguchi, Kazuhiro ^a   Tatsuda, Yoshiki ^a   Usui, Shigeyuki ^a   Hirano, Kazuyuki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Mevalonate pathway; PC 3 cells; Prostate cancer; Urokinase type plasminogen activator

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GERANYLGERANYL PYROPHOSPHATE; GGTI 286; LUCIFERASE; MESSENGER RNA; PAMIDRONIC ACID; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DIPHOSPHONATES; DITERPENES; DOWN-REGULATION; HUMANS; MALE; POLYISOPRENYL PHOSPHATES; PROSTATIC NEOPLASMS; RNA, MESSENGER; SERINE PROTEINASE INHIBITORS; TRANSCRIPTION, GENETIC; URINARY PLASMINOGEN ACTIVATOR;

EID: 37549001685     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Fleisch H, Russell RG and Francis MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165: 1262-1264, 1969.
2. Fleisch H: Development of bisphosphonates. Breast Cancer Res 4: 30-34, 2002.
3. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J and Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785-1791, 1996.
4. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW and Finkelstein JS: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948-955, 2001.
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Zheng M: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882, 2004.
6. Saad F: Zoledronic acid: past, present and future roles in cancer treatment. Future Oncol 1: 149-159, 2005.
7. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998.
8. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K and Namiki M: Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol 169: 281-282, 2003.
9. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM and Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000.
10. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001.
11. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K and Murata Y: Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 62: 6015-6020, 2002.
12. Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M and Irimajiri K: A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci 73: 2655-2664, 2003.
13. Asahi H, Mizokami A, Miwa S, Keller ET, Koshida K and Namiki M: Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int J Urol 13: 593-600, 2006.
14. Matsunaga S, Iguchi K, Usui S and Hirano K: Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells. Anticancer Res 27: 927-932, 2007.
15. Valenti MT, Bertoldo F, Dalle Carbonare L, Azzarello G, Zenari S, Zanatta M, Balducci E, Vinante O and Lo Cascio V: The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene? BMC Cancer 6: 49, 2006.
16. Virtanen SS, Vaananen HK, Harkonen PL and Lakkakorpi PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62: 2708-2714, 2002.
17. Oades GM, Senaratne SG, Clarke IA, Kirby RS and Colston KW: Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170: 246-252, 2003.
18. Iguchi K, Nakano T, Usui S and Hirano K: Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett 237: 223-233, 2006.
19. Iguchi K, Matsunaga S, Nakano T, Usui S and Hirano K: Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells. Anticancer Res 26: 2977-2981, 2006.
20. Sheng S: The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20: 287-296, 2001.
21. Van Veldhuizen PJ, Sadasivan R, Cherian R and Wyatt A: Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 312: 8-11, 1996.
22. Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K and Hirano K: Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol Pharm Bull 24: 226-230, 2001.
23. Schweinitz A, Steinmetzer T, Banke IJ, Arlt MJ, Sturzebecher A, Schuster O, Geissler A, Giersiefen H, Zeslawska E, Jacob U, Kruger A and Sturzebecher J: Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 279: 33613-33622, 2004.
24. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M and Rao JS: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280: 36529-36540, 2005.
25. Kranenburg O, Gebbink MF and Voest EE: Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 1654: 23-37, 2004.
26. Verde P, Boast S, Franze A, Robbiati F and Blasi F: An upstream enhancer and a negative element in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 16: 10699-10716, 1988.
27. Nerlov C, De Cesare D, Pergola F, Caracciolo A, Blasi F, Johnsen M and Verde P: A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 11: 4573-4582, 1992.
28. Reuning U, Wilhelm O, Nishiguchi T, Guerrini L, Blasi F, Graeff H and Schmitt M: Inhibition of NF-κB-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res 23: 3887-3893, 1995.
29. Lengyel E, Gum R, Stepp E, Juarez J, Wang H and Boyd D: Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem 61: 430-443, 1996.
30. Ibanez-Tallon I, Ferrai C, Longobardi E, Facetti I, Blasi F and Crippa MP: Binding of Sp1 to the proximal promoter links constitutive expression of the human uPA gene and invasive potential of PC3 cells. Blood 100: 3325-3332, 2002.
31. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Takeuchi M, Kikuchi S, Ohno S and Yoshimura A: Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun 297: 419-424, 2002.
32. Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K and Hirata M: The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NF-κB pathway in osteosarcoma cells. Br J Pharmacol 146: 633-641, 2005.
33. Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, Kessler P and Neukam FW: Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 42: 888-892, 2006.